A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed

被引：0
|
作者：
Halabi, Susan
Lin, Chen-Yen
Small, Eric Jay
Armstrong, Andrew J.
Kaplan, Ellen B.
Petrylak, Daniel Peter
Sternberg, Cora N.
Shen, Liji
Oudard, Stephane
De Bono, Johann Sebastian
Sartor, A. Oliver
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Duke Univ, Durham, NC USA
[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[4] Duke Univ, Div Med Oncol & Urol, Duke Canc Inst, Durham, NC USA
[5] Duke Univ, Div Med Oncol & Urol, Duke Prostate Ctr, Durham, NC USA
[6] Yale Univ, Smilow Canc Hosp, New Haven, CT USA
[7] San Camillo & Forlanini Hosp, Rome, Italy
[8] Sanofi, Malvern, PA USA
[9] Hop Europeen Georges Pompidou, Paris, France
[10] Inst Canc Res, London SW3 6JB, England
[11] Tulane Canc Ctr, New Orleans, LA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.24
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
24
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Patient preference between Cabazitaxel and Docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC): Results from the CABADOC randomized trial
    Fizazi, K.
    Delva, R.
    Gravis, G.
    Baciarello, G.
    Theodore, C.
    Gross-Goupil, M.
    Bompas, E.
    Lobbedez, F. Joly
    Tazi, Y.
    L'Haridon, T.
    Hon, T. Nguyen Tan
    Barthelemy, P.
    Culine, S.
    Berdah, J-F.
    Deblock, M.
    Beuzeboc, P.
    Flechon, A.
    Cheneau, C.
    Martineau, G.
    Borget, I.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] Impact of comorbidity on outcome in men with metastatic castrate-resistant prostate cancer (mCRPC)
    Zist, A.
    Amir, E.
    Ocana, A.
    Seruga, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S703 - S703
  • [33] EXTREQOL Identifies Ongoing Challenges in Maximising Quality of Survival in Men with Metastatic Castrate-resistant Prostate Cancer
    Jenkins, V.
    Payne, H.
    Mason, M.
    May, S.
    Matthews, L.
    Catt, S.
    CLINICAL ONCOLOGY, 2018, 30 (06) : 331 - 333
  • [34] Radiopharmaceutical and Chemotherapy Combinations in Metastatic Castrate-Resistant Prostate Cancer: A New Beginning?
    Sartor, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) : 2417 - 2418
  • [35] The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer
    Papadopoulos, Efthymios
    Wong, Andy Kin On
    Law, Sharon Hiu Ching
    Zhang, Lindsey Ze Jing
    Breunis, Henriette
    Emmenegger, Urban
    Alibhai, Shabbir M. H.
    PLOS ONE, 2023, 18 (06):
  • [36] Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer
    Dorff, T. B.
    Crawford, E. D.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 31 - 38
  • [37] A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer (CRPC)
    Pili, R.
    Haggman, M.
    Stadler, W. M.
    Gingrich, J. R.
    Assikis, V. J.
    Bjork, A.
    Forsberg, G.
    Carducci, M. A.
    Armstrong, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] ASSOCIATION OF SARCOPENIA VERSUS OBESITY WITH SURVIVAL IN METASTATIC OR CASTRATE-RESISTANT PROSTATE CANCER
    Huelster, Heather
    Xu, Mark
    Hatcher, Jeremy
    Avulova, Svetlana
    Glaser, Zachary
    Moses, Kelvin
    JOURNAL OF UROLOGY, 2020, 203 : E562 - E562
  • [39] Association of Overall Survival with Glycolytic Activity of Castrate-Resistant Prostate Cancer Metastases Response
    Vargas, Hebert Alberto
    Wassberg, Cecilia
    Fox, Josef J.
    Wibmer, Andreas
    Goldman, Debra A.
    Kuk, Deborah
    Gonen, Mithat
    Larson, Steven M.
    Morris, Michael J.
    Scher, Howard I.
    Hricak, Hedvig
    RADIOLOGY, 2015, 274 (02) : 625 - 625
  • [40] Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).
    Baciarello, Giulia
    Delva, Remy
    Gravis, Gwenaelle
    Tazi, Youssef
    Theodore, Christine
    Gross-Goupil, Marine
    Bompas, Emmanuelle
    Joly, Florence
    Lharidon, Tifenn
    Thierry Nguyen Tan Hon
    Barthelemy, Philippe
    Culine, Stephane
    Berdah, Jean Francois
    Deblock, Mathilde
    Beuzeboc, Philippe
    Flechon, Aude
    Cheneau, Caroline
    Martineau, Geraldine
    Borget, Isabelle
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345